Navigation Links
Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
Date:12/15/2008

ell as more aggressive management of HDL and triglycerides.

About the TRILIPIX Clinical Trial Program

The FDA's approval of TRILIPIX was based on the largest clinical trial program to date designed to evaluate the efficacy and safety of a fibrate in combination with various statins. The efficacy and safety of TRILIPIX in combination with the three most commonly prescribed statins -- rosuvastatin, atorvastatin and simvastatin -- was evaluated in three randomized, multicenter, double-blind, controlled, 12-week Phase III studies, totaling 2,698 patients with mixed dyslipidemia. Patients included in the studies had multiple lipid problems, with an LDL > 130 mg/dL, triglycerides > 150 mg/dL and HDL less than 40 mg/dL for men and less than 50 mg/dL for women. A total of 1,911 patients who completed one of the 12-week studies subsequently enrolled in a 52-week long-term, open-label extension study.

The Phase III combination studies all met their primary endpoints. Combination therapy significantly improved HDL and triglycerides compared to statin therapy alone, and significantly improved LDL compared to TRILIPIX alone. All of the combinations and the statins had clinically meaningful reductions in LDL.

"Physicians told us that they needed data supporting the use of a fibrate with statins to help them more aggressively manage their patients' lipid problems," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott. "Abbott built a robust clinical program to support the use of TRILIPIX, and its approval adds a new option to Abbott's growing dyslipidemia portfolio which provides treatments to comprehensively help address all three key lipids."

Abbott and AstraZeneca are working together to develop a fixed-dose combination of Abbott's TRILIPIX and AstraZeneca's CRESTOR(R) (rosuvastatin calcium) with plans to submit a new drug application to t
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... development of it’s new program “Designing Secure Healthcare Systems” This three-day, highly ... technology leaders from healthcare organizations with access to the tactics, techniques and practices ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from ... Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses ... the report, the new study showed that harvesting stem cell-rich bone marrow from the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Illinois Health & ... July 31. , The acquisition includes all of IBAM NA’s cyclotron sites and ... have both, a robust regionally located business, as well as a large manufacturing hub ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... DENVER, June 24 The National Sports Center for the Disabled and American ... Classic from Friday, July 17th to Sunday, July 19th at the Winter Park ... with a wide variety of well-marked trails for all levels of riders and ... , World Class Mountain Biking! , ...
... researchers say , , WEDNESDAY, June 24 (HealthDay ... well in an early clinical trial against breast, ovarian ... to developing these malignancies. , Women who carry BRCA1 ... and ovarian cancer, and among men these mutations are ...
... 24 Validation and Compliance Institute (VCI), which provides ... industries, will offer a series of Dietary Supplement Good ... division of NSF International. , , ... GMP regulations for dietary supplements, which the US Food ...
... 24 Speaker Nancy Pelosi held a brief a press availability ... , Jim Douglas of Vermont , and Chris Gregoire ... to discuss health care reform. Below are their remarks: ... indeed to welcome three very distinguished governors to The Speaker,s Office - ...
... , ROCHESTER, Minn., June 24 The Mayo Clinic ... collaborative symposium on innovations in health care experience and ... open to the public. It will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
... biomarkers in patients with only mild memory problems , ... disease can be detected in the cerebrospinal fluid in ... study suggests. , University of Gothenburg researchers analyzed cerebrospinal ... typical pattern of biomarkers known as the "CSF AD ...
Cached Medicine News:Health News:18th Annual Fat Tire Classic Benefiting the National Sports Center for the Disabled & the American Red Cross Mile High July 17th - 19th, 2009 2Health News:New Cancer Drug Fights Tumors in Those With BRCA Mutations 2Health News:New Cancer Drug Fights Tumors in Those With BRCA Mutations 3Health News:Validation & Compliance Institute, LLC, to Provide Dietary Supplement GMP Training for NSF International 2Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 2Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 3Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 4Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 2Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 3Health News:Clues to Alzheimer's Spotted Earlier in Disease 2
(Date:8/3/2015)... NEWPORT NEWS, Va. , Aug. 3, 2015 ... will be joining Orthopaedic & Spine Center ... help them to manage their chronic pain through ... Dr. Robinson is a Fellowship-trained, certified medical ... and pain medicine. His vast experience ranges from ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... BELGRADE, Mont., July 26, 2011 Bacterin ... a leader in the development of revolutionary bone graft material ... call on Thursday, August 11, at 4:30 p.m. Eastern time ... 2011. Financial results will be issued in a press release ...
... America, Inc. today announced plans to debut expanded software ... EasyCell® assistant Automated Cell Imaging Analyzer during ... Conference and Clinical Lab Expo July 24 - 28 ... hematology portfolio can be seen at Sysmex,s exhibit booth, ...
Cached Medicine Technology:Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET 2Sysmex America to Debut Expanded Software Products for Middleware and Cell Image Analysis at AACC 2011 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: